Shopping Cart
Remove All
Your shopping cart is currently empty
Gontivimab (Synonyms: VR-465, VR465, ALX-0171, ALX0171)
Catalog No. T77027 Copy Product Info
🥰Excellent
Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections.
Gontivimab
Copy Product Info🥰Excellent
Catalog No. T77027
Synonyms VR-465, VR465, ALX-0171, ALX0171
Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections.
Gontivimab
Cas No. 1257358-38-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | In Stock | In Stock | |
| 5 mg | $483 | In Stock | In Stock | |
| 10 mg | $692 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections. |
| Targets&IC50 | RSV A strains:0.1 nM |
| In vitro | Gontivimab (0-100,000 nM) exhibited antiviral effects with IC50 values of 0.1 nM and 0.4 nM against RSV-A and RSV-B 18537 strains, respectively.[1] Gontivimab binds to antigenic site II of the F protein.[1] Gontivimab binds to antigenic site II of the F protein.[1] |
| In vivo | Gontivimab (1-68 mg/kg; administered intranasally or by nebulization) reduces RSV load in the nasal cavity and lungs of rats.[1] Gontivimab has been shown to reduce RSV load in the nasal cavity and lungs of rats. [1] |
| Synonyms | VR-465, VR465, ALX-0171, ALX0171 |
| Reactivity | Virus |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | RSV-F |
| Molecular Weight | 42.14 kDa |
| Cas No. | 1257358-38-5 |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Gontivimab | purchase Gontivimab | Gontivimab cost | order Gontivimab | Gontivimab in vivo | Gontivimab in vitro | Gontivimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.